TLDR
- A new publicly traded investment vehicle focused on AI data center acquisitions is being launched by Blackstone, with capital targets in the tens of billions
- Initial fundraising efforts are targeting sovereign wealth funds and large institutional capital sources
- Competing against Brookfield, Blackstone has submitted a bid exceeding €8 billion to acquire Volkswagen’s Everllence SE heavy diesel engine division
- A collaborative funding agreement between Blackstone Life Sciences and Johnson & Johnson will support development of bleximenib, an experimental AML cancer treatment
- An Outperform rating with $179 price target was assigned to Blackstone by RBC Capital on February 23
The investment management powerhouse is rolling out a fresh publicly traded acquisition platform centered on AI data center assets. This initiative aims to democratize access to AI infrastructure investments for everyday investors — a sector Blackstone is positioning itself to control.
Initial capital formation will target sovereign wealth funds and large institutional backers. Following this phase, the firm intends to scale up by attracting tens of billions from a more diverse investor base.
The strategy is bold. However, skepticism exists regarding market timing.
Certain market participants worry that massive AI training complexes constructed in remote locations may lose relevance as technological requirements shift. Blackstone is confronting these doubts directly.
This initiative reflects a wider push to expand beyond the firm’s conventional client roster of pension funds and university endowments. Individual investors are now a key focus area.
Volkswagen Unit Bid
On the mergers and acquisitions front, Blackstone alongside Brookfield Asset Management (NYSE: BAM) have both tendered offers of no less than €8 billion ($9.4 billion) for controlling ownership in Volkswagen’s Everllence SE division.
Everllence specializes in marine propulsion systems and industrial power generation turbines. Volkswagen has been pursuing a sale of this business as part of a broader corporate restructuring initiative aimed at enhancing margins.
Additional contenders include Advent International, Bain Capital, EQT AB, and CVC Capital Partners — each having progressed to subsequent bidding stages.
A transaction remains uncertain. Sources cited by Bloomberg indicated that discussions are continuing.
Biotech and Analyst Coverage
On February 23, Blackstone Life Sciences revealed a joint funding partnership with Johnson & Johnson to support clinical trials of bleximenib, an oral investigational therapy for acute myeloid leukemia patients.
AML represents the most prevalent form of acute leukemia among adult populations and carries the poorest survival statistics across all leukemia categories. Company leadership characterized it as an exceptionally challenging disease to manage.
This marks the inaugural co-funding collaboration between BXLS and Johnson & Johnson, representing a significant development for Blackstone’s life sciences division.
On the same date, RBC Capital commenced coverage of Blackstone with an Outperform recommendation and established a $179 price objective.
RBC communicated to clients that Blackstone possesses a “first-mover advantage” as the initial alternative asset manager to establish a dedicated private wealth division. The firm anticipates Blackstone will be a sustained beneficiary of expanding retail participation and stabilization in commercial real estate markets.
Blackstone’s operations span four primary business lines: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions.
BX stock declined 3.88% on February 27, coinciding with news releases regarding the AI data center platform and Volkswagen acquisition pursuit.
